EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

CHROMAgar™ LIN-R as an efficient screening tool to assess the prevalence of linezolid-resistant enterococci in German hospital patients—a multicentre study approach, 2021–2022

Jennifer K Bender iD, Elsa Baufeld, Karsten Becker iD, Heike Claus, Anna Dudakova, Achim Dörre, Nikoletta Fila, Carola Fleige, Axel Hamprecht, Armin Hoffmann, Michael Hogardt, Achim J Kaasch und 16 weitere

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad218 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Jennifer K Bender und 27 weiteren Autor:innen. Beteiligte Einrichtung: Nosocomial Pathogens and Antibiotic Resistances Unit, Department of Infectious Diseases, National Reference Centre for Staphylococci and Enterococci,…. Hauptthemen laut MEDLINE: Gram-Positive Bacterial Infections, Enterococcus faecium. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Federal Ministry of Health, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In recent years, an increasing number of linezolid-resistant enterococci (LRE) was recognized at the German National Reference Centre (NRC) for Enterococci. National guidelines on infection prevention recommend screening for LRE in epidemiologically linked hospital settings without referring to a reliable and rapid diagnostic method. Since 2020, CHROMAgar™ provide a chromogenic linezolid screening agar, LIN-R, suitable to simultaneously screen for linezolid-resistant staphylococci and enterococci.

Objectives

To assess the applicability of CHROMAgar™ LIN-R in clinical settings for detecting LRE directly from patient material and to infer prevalence rates of LRE amongst German hospital patients.

Methods

During the 3-month trial period, clinical samples were plated on CHROMAgar™ LIN-R. Antimicrobial susceptibility testing was performed using VITEK2 or disc diffusion. At the NRC, linezolid resistance was determined by broth microdilution, multiplex-PCR for cfr/optrA/poxtA and by a restriction-based assay for 23S rDNA mutations.

Results

The 12 participating study sites used 13 963 CHROMAgar™ LIN-R plates during the study period. Of 442 presumptive LRE, 192 were confirmed by phenotypic methods. Of these, 161 were received by the NRC and 121 (75%) were verified as LRE. Most of LR-E. faecium 53/81 (65%) exhibited a 23S rRNA gene mutation as the sole resistance-mediating mechanism, whereas optrA constituted the dominant resistance trait in LR-E. faecalis [39/40 (98%)]. Prevalence of LRE across sites was estimated as 1% (ranging 0.18%–3.7% between sites).

Conclusions

CHROMAgar™ LIN-R represents a simple and efficient LRE screening tool in hospital settings. A high proportion of false-positive results demands validation of linezolid resistance by a reference method.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gram-Positive Bacterial InfectionsEnterococcus faeciumHumansLinezolidAnti-Bacterial AgentsPrevalenceDrug Resistance, BacterialEnterococcusHospitalsMicrobial Sensitivity TestsEnterococcus faecalis

Substanzen

LinezolidAnti-Bacterial Agents

Autor:innen und Institutionen

  • Nosocomial Pathogens and Antibiotic Resistances Unit, Department of Infectious Diseases, National Reference Centre for Staphylococci and Enterococci, Robert Koch Institute, Wernigerode, Germany.
  • Friedrich Loeffler Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.
  • Institute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany.
  • Institute for Medical Microbiology and Virology, University Medical Center Göttingen, Göttingen, Germany.
  • Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
  • Institute of Medical Microbiology and Hygiene, University of Tübingen, Tübingen, Germany.

ORCID-Profile: Jennifer K Bender, Karsten Becker, Ernst Molitor, Nico T Mutters, Bernd Neumann, Holger Rohde

Förderung

  • Federal Ministry of Health, Germany

Zitieren

APA

Bender, J. K., Baufeld, E., Becker, K., Claus, H., Dudakova, A., Dörre, A., Fila, N., Fleige, C., Hamprecht, A., Hoffmann, A., Hogardt, M., Kaasch, A. J., Kola, A., Kriebel, N., Layer-Nicolaou, F., Marschal, M., Molitor, E., Mutters, N. T., Liese, J., …, & Werner, G. (2023). CHROMAgar™ LIN-R as an efficient screening tool to assess the prevalence of linezolid-resistant enterococci in German hospital patients—a multicentre study approach, 2021–2022. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad218

Vancouver

Bender JK, Baufeld E, Becker K, Claus H, Dudakova A, Dörre A, et al. CHROMAgar™ LIN-R as an efficient screening tool to assess the prevalence of linezolid-resistant enterococci in German hospital patients—a multicentre study approach, 2021–2022. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad218

BibTeX
@article{Bender2023,
  author = {Bender, Jennifer K and Baufeld, Elsa and Becker, Karsten and Claus, Heike and Dudakova, Anna and Dörre, Achim and Fila, Nikoletta and Fleige, Carola and Hamprecht, Axel and Hoffmann, Armin and Hogardt, Michael and Kaasch, Achim J and Kola, Axel and Kriebel, Nancy and Layer-Nicolaou, Franziska and Marschal, Matthias and Molitor, Ernst and Mutters, Nico T and Liese, Jan and Nelkenbrecher, Claudia and Neumann, Bernd and Rohde, Holger and Steinmann, Jörg and Sörensen, Michael and Thelen, Philipp and Weig, Michael and Zautner, Andreas E and Werner, Guido},
  title = {CHROMAgar™ LIN-R as an efficient screening tool to assess the prevalence of linezolid-resistant enterococci in German hospital patients—a multicentre study approach, 2021–2022},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad218}
}
Kostenlos starten →